SCHEMBL4908272

SCHEMBL4908272

CCOC(=O)c1cncc(-c2ccc(N)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 2/20 0.59
MAOA P21397 1/20 0.59
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MKNK1 Q9BUB5 2/20 0.48
MKNK2 Q9HBH9 2/20 0.48
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640338 0.87 CYP2C9 (0.59) CYP2C9CYP2C19MAPTSMN1; SMN2MKNK1
SCHEMBL640459 0.86 CYP2C9 (0.55) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL14395360 0.86 CYP2C9 (0.55) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL8622944 0.86 CYP2C19 (0.57) CYP1A2CYP3A4CYP2C9CYP2C19MEN1
SCHEMBL5372083 0.85 CYP2C9 (0.65) LMNACYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL6434460 0.85 SMN1; SMN2 (0.56) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL640295 0.84 CYP11B1 (0.60) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL4908827 0.84 CYP2C9 (0.52) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL640303 0.82 MAOB (0.54) CYP2C9CYP2C19MEN1MAPTKMT2A
SCHEMBL3664506 0.82 CYP2C19 (0.68) LMNACYP1A2CYP3A4MAOACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269214-A1 Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors ASTRAZENECA AB (SE) 2008-10-30 US disclosed
EP-1861393-A2 PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS AstraZeneca AB (SE) 2007-12-05 EP disclosed
WO-2006092599-A2 PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS ASTRAZENECA AB (SE) 2006-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269214-A1 Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors TOP1, TOP2A, TOP2B LMNA 1835/4885CYP1A2 365/4885CYP3A4 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.